The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings
Abstract
PURPOSE: To determine the immunogenicity and antitumor activity of a vaccine consisting of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, Oncophage; Antigenics, Inc, Woburn, MA) in metastatic (American Joint Committee on Cancer stage IV) melanoma patients. PATIENTS AND METHODS: Sixty-four patients had surgical resection of metastatic tissue required for vaccine production, 42 patients were able to receive the vaccine, and 39 were assessable after one cycle of vaccination (four weekly injections). In 21 patients, a second cycle (four biweekly injections) was given because no progression occurred. Antigen-specific antimelanoma T-cell response was assessed by enzyme-linked immunospot (ELISPOT) assay on peripheral blood mononuclear cells (PBMCs) obtained before and after vaccination. Immunohistochemical analyses of tumor tissues were also performed. RESULTS: No treatment-related toxicity was observed. Of 28 patients with measurable disease, two had a complete response (CR) and three had stable disease (SD) at the end of follow-up. Duration of CR was 559+ and 703+ days, whereas SD lasted for 153, 191, and 272 days, respectively. ELISPOT assay with PBMCs of 23 subjects showed a significantly increased number of postvaccination melanoma-specific T-cell spots in 11 patients, with clinical responders displaying a high frequency of increased T-cell activity. Immunohistochemical staining of melanoma tissues from which vaccine was produced revealed high expression of both HLA class I and melanoma antigens in seven of eight clinical responders (two with CR, three with SD, and the three with long-term disease-free survival) and in four of 12 nonresponders. CONCLUSION: Vaccination of metastatic melanoma patients with autologous HSPPC-96 is feasible and devoid of significant toxicity. This vaccine induced clinical and tumor-specific T-cell responses in a significant minority of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1669 · Cited by 1,226
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,092
Self-citationSrivastava, P. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064801 · Cited by 850
Self-citationA Mechanism for the Specific Immunogenicity of Heat Shock Protein-Chaperoned Peptides
Suto, R., & Srivastava, P. K. (1995) · Science · doi:10.1126/science.7545313 · Cited by 823
Self-citationMarchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Self-citationImmunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations
Tamura, Y., Peng, P., Liu, K., Daou, M., & Srivastava, P. K. (1997) · Science · doi:10.1126/science.278.5335.117 · Cited by 680
Self-citationRomero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Ferrone, S., & Marincola, F. M. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80033-6 · Cited by 474
Castellino, F., Boucher, P. E., Eichelberg, K., Mayhew, M., Rothman, J. E., Houghton, A. N., & Germain, R. N. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.11.1957 · Cited by 404
Eton, O., Legha, S. S., Bedikian, A. Y., Lee, J. J., Buzaid, A. C., Hodges, C., Ring, S. E., Papadopoulos, N. E., Plager, C., East, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.044 · Cited by 370
Singh-Jasuja, H., Toes, R. E. M., Spee, P., Münz, C., Hilf, N., Schoenberger, S. P., Ricciardi-Castagnoli, P., Neefjes, J., Rammensee, H.-G., Arnold-Schild, D., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.11.1965 · Cited by 348
Mihm, M. C., Clemente, C. G., & Cascinelli, N. (1996) · PubMed · Cited by 318
Self-citationRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Seipp, C. A., Einhorn, J. H., White, D. E., & Steinberg, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.968 · Cited by 312
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., & Marincola, F. M. (1997) · PubMed · Cited by 277
Self-citationJanetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J. J., & Srivastava, P. K. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001015)88:2<232::aid-ijc14>3.0.co;2-8 · Cited by 246
Self-citationIshii, T., Udono, H., Yamano, T., Ohta, H., Uenaka, A., Ono, T., Hizuta, A., Tanaka, N., Srivastava, P. K., & Nakayama, E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.3.1303 · Cited by 235
Self-citationAnichini, A., Molla, A., Mortarini, R., Tragni, G., Bersani, I., Di Nicola, M., Gianni, A. M., Pilotti, S., Dunbar, R., Cerundolo, V., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.651 · Cited by 190
Self-citationNagorsen, D., Keilholz, U., Rivoltini, L., Schmittel, A. H., Letsch, A., Asemissen, A. M., Berger, G., Buhr, H. J., Thiel, E., & Scheibenbogen, C. (2000) · PubMed · Cited by 137
Self-citationScheibenbogen, C., Romero, P. J., Rivoltini, L., Herr, W., Schmittel, A. H., Cerottini, J., Woelfel, T., Eggermont, A. M. M., & Keilholz, U. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00257-x · Cited by 133
Self-citationHa, P., Schwarz, S. L., Wunderlich, J. R., & Rosenberg, S. A. (1998) · PubMed · Cited by 110
Lewis, J. J., Janetzki, S., Schaed, S. G., Panageas, K. S., Wang, S., Williams, L. J., Meyers, M. L., Butterworth, L., Livingston, P. O., Chapman, P. B., et al. (2000) · International Journal of Cancer · Cited by 106
Self-citationHBV-specific peptide associated with heat-shock protein gp96
Meng, S., Gao, T., Gao, G. F., & Tien, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04050-2 · Cited by 74
Pende, D., Accame, L., Pareti, L., Mazzocchi, A., Moretta, A., Parmiani, G., & Moretta, L. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199808)28:08<2384::aid-immu2384>3.0.co;2-l · Cited by 72
Self-citationImmunological Gene Therapy with ex Vivo Gene-Modified Tumor Cells: A Critique and a Reappraisal
Parmiani, G., Rodolfo, M., & Melani, C. C. (2000) · Human Gene Therapy · doi:10.1089/10430340050032375 · Cited by 64
Self-citationDo human cancers express sharedprotectiveantigens? or The necessity of remembrance of things past
Srivastava, P. K. (1996) · Seminars in Immunology · doi:10.1006/smim.1996.0038 · Cited by 60
Self-citation
Cited by
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Medical application of functionalized magnetic nanoparticles
Ito, A., Shinkai, M., Honda, H., & Kobayashi, T. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.100.1 · Cited by 1,470
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications
Ciocca, D. R., & Calderwood, S. K. (2005) · Cell Stress & Chaperones · doi:10.1379/csc-99r.1 · Cited by 1,404
Kapur, S., Phillips, A. G., & Insel, T. R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.105 · Cited by 980
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
Hu, C., Yang, J., Qi, Z., Wu, H., Wang, B., Zou, F., Mei, H., Liu, J., Wang, W., & Liu, Q. (2022) · MedComm · doi:10.1002/mco2.161 · Cited by 779
Metadata
- Authors
- Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, M. R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., Carrabba, M., Scita, G., Santantonio, C., Pilla, L., Tragni, G., Lombardo, C., Arienti, F., Marchianò, A., Queirolo, P., Bertolini, F., Cova, A., Lamaj, E., Ascani, L., Camerini, R., Corsi, M., Cascinelli, N., Lewis, J. J., Srivastava, P., & Parmiani, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-10-15
- Volume
- 20
- Issue
- 20
- Pages
- 4169-4180
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2099735866
- Cited by
- 387
- References
- 28
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.